Hernia Procedures Except Inguinal and Femoral with MCC DRG Reimbursement

DRG 353 encompasses non-inguinal, non-femoral hernia procedures with a Major Complication or Comorbidity, covering complex abdominal wall hernias and admissions requiring higher-level management. This classification matters for inpatient reimbursement because the Major Complication or Comorbidity status elevates the payment weight to account for increased resource use and clinical complexity.

DRG 353 Overview

DRG 353 covers inpatient admissions for hernia procedures other than inguinal and femoral hernias when a Major Complication or Comorbidity is present, typically involving complex or atypical abdominal wall hernias and associated acute conditions. This Diagnosis-Related Group captures higher resource use due to increased perioperative risk, extended operative time, or need for advanced supportive care. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative weight and inpatient reimbursement, reflecting greater expected costs of care.

Acute perioperative optimization and risk-stratification studies: trials assessing protocols for preoperative optimization (eg, management of cardiopulmonary comorbidities, anticoagulation strategies, nutritional status, and sepsis control) and intraoperative interventions (anesthesia techniques, fluid management, and surgical approach) in patients undergoing non-inguinal/non-femoral hernia repairs with major complications. The patient population includes older adults and those with significant comorbid conditions or incarcerated/strangulated hernias that led to MCC coding; studies measure short-term morbidity, ICU needs, and in-hospital mortality. This research helps hospitals and payers understand modifiable factors that reduce length of stay, avoid escalation of care, and improve resource allocation for high-cost admissions coded to DRG 353.
Comparative effectiveness trials of surgical technique and timing in complicated ventral, incisional, or diaphragmatic hernias: prospective studies comparing open versus laparoscopic or hybrid repairs, use of primary repair versus biologic/synthetic mesh, and the impact of immediate versus delayed definitive repair for contaminated or strangulated fields. Enrolled patients are those admitted with complex non-inguinal hernias complicated by bowel compromise, contamination, or other MCC-level issues; outcomes include reoperation rates, surgical site infection, hernia recurrence, and total inpatient costs. Findings directly inform clinical pathways and payer decisions about which techniques or timing strategies provide the best balance of clinical benefit and cost-effectiveness for high-acuity hernia admissions.
Post-discharge outcomes and utilization research including readmission, wound-care needs, and long-term functional recovery: observational cohorts or pragmatic trials tracking patients discharged after complicated hernia procedures to quantify 30- and 90-day readmissions, home health and wound-care utilization, opioid and analgesic use, and return to baseline activities. The population focuses on patients who had MCC-level complications during index hospitalization, as they have higher risk of post-discharge complications and resource use. Results are relevant to providers and payers for designing discharge planning, transitional care interventions, and bundled-payment models to reduce costly readmissions and downstream utilization associated with DRG 353 admissions.

Acute perioperative optimization and risk-stratification studies: trials assessing protocols for preoperative optimization (eg, management of cardiopulmonary comorbidities, anticoagulation strategies, nutritional status, and sepsis control) and intraoperative interventions (anesthesia techniques, fluid management, and surgical approach) in patients undergoing non-inguinal/non-femoral hernia repairs with major complications. The patient population includes older adults and those with significant comorbid conditions or incarcerated/strangulated hernias that led to MCC coding; studies measure short-term morbidity, ICU needs, and in-hospital mortality. This research helps hospitals and payers understand modifiable factors that reduce length of stay, avoid escalation of care, and improve resource allocation for high-cost admissions coded to DRG 353.
Comparative effectiveness trials of surgical technique and timing in complicated ventral, incisional, or diaphragmatic hernias: prospective studies comparing open versus laparoscopic or hybrid repairs, use of primary repair versus biologic/synthetic mesh, and the impact of immediate versus delayed definitive repair for contaminated or strangulated fields. Enrolled patients are those admitted with complex non-inguinal hernias complicated by bowel compromise, contamination, or other MCC-level issues; outcomes include reoperation rates, surgical site infection, hernia recurrence, and total inpatient costs. Findings directly inform clinical pathways and payer decisions about which techniques or timing strategies provide the best balance of clinical benefit and cost-effectiveness for high-acuity hernia admissions.
Post-discharge outcomes and utilization research including readmission, wound-care needs, and long-term functional recovery: observational cohorts or pragmatic trials tracking patients discharged after complicated hernia procedures to quantify 30- and 90-day readmissions, home health and wound-care utilization, opioid and analgesic use, and return to baseline activities. The population focuses on patients who had MCC-level complications during index hospitalization, as they have higher risk of post-discharge complications and resource use. Results are relevant to providers and payers for designing discharge planning, transitional care interventions, and bundled-payment models to reduce costly readmissions and downstream utilization associated with DRG 353 admissions.

OpenPayer

Summary & Overview

Hernia Procedures Except Inguinal and Femoral with MCC: Inpatient Reimbursement Overview

DRG 353 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes